NBTX - Nanobiotix S.A.
市前：
| 前收市價 | 4.58 |
| 開市 | 5.23 |
| 買盤 | 5.04 x 1300 |
| 賣出價 | 5.16 x 900 |
| 今日波幅 | 5.11 - 5.43 |
| 52 週波幅 | 1.75 - 7.76 |
| 成交量 | |
| 平均成交量 | 698,022 |
| 市值 | 189.675M |
| Beta 值 (5 年，每月) | 1.72 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.68 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 8.71 |
BenzingaNanobiotix Stock Triples In Trading Session: What's Going On With Stock On Friday
Nanobiotix (NASDAQ: NBTX) shares gained more than 200% on Friday trading after it entered into final contract negotiations with a major global pharmaceutical company. In its Q4 earnings release, Nanobiotix raised going concerns. The company noted net losses of €57.0 million in 2022 and a net decrease in cash and cash equivalents of €42.5 million in 2022. Nanobiotix stock is gaining on heavy volume, with a session volume of 30.262 million shares traded. The company agreed to a non-binding term sh
BenzingaNanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients
Nanobiotix (NASDAQ: NBTX) announced updated data from phase 1 Study 1100 of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell carcinoma that is resistant to prior immunotherapy. Reported data included 28 patients, with 21 evaluable for early signs of efficacy. Treatment remained feasible and well-tolerated. Objective reduction from baseline in target lesions was observed in 71.43% of evaluable patients (15/21). 42.86% of evaluab
BenzingaNanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
Nanobiotix (NASDAQ: NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell carcinoma that is resistant to prior immunotherapy. The combo includes NBTXR3 plus Merck & Co Inc's (NYSE: MRK) Keytruda pembrolizumab or Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab). The combined dose escalation and dose expansion parts of Study 1100 are expected to enroll up to 141 patients.